Möchten Sie immer auf dem neuesten Stand bleiben?

Scientist Dario Crosetto challenges CERN to a ‘Known Dataset Test’ at the TBPET 2026 Conference to prove 3D-Flow can save >$12B and millions of lives

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,...

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent...

Messino Cancer Centers Opens New Asheville Clinic

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer

“Global Oncology Biosimilars Market” is projected to grow from $9.6 billion in 2025 to $17.5 billion by the end of 2030, at a CAGR of 12.6%.

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal...

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.